Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation by Vitillo, L et al.
Stem Cell Reports
ReportIntegrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem
Cells from Apoptosis, Detachment, and Differentiation
Loriana Vitillo,1,3 Melissa Baxter,1,4 Banu Iskender,1,5 Paul Whiting,2,6 and Susan J. Kimber1,*
1North West Embryonic Stem Cell Centre, Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, UK
2Pfizer Neusentis, The Portway Building, Granta Park, Cambridge CB21 6GS, UK
3Present address: Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory for Regenerative Medicine, University of
Cambridge, Cambridge CB2 0SZ, UK
4Present address: School of Medicine and Dentistry, University of Central Lancashire, Preston PR1 2HE, UK
5Present address: Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri 38039, Turkey
6Present address: Alzheimer’s Research UK UCL Drug Discovery Institute, University College London, London WC1E 6BT, UK
*Correspondence: sue.kimber@manchester.ac.uk
http://dx.doi.org/10.1016/j.stemcr.2016.07.006SUMMARYHuman embryonic stem cells (hESCs) can be maintained in a fully defined niche on extracellular matrix substrates, to which they attach
through integrin receptors. However, the underlying integrin signalingmechanisms, and their contribution to hESC behavior, are largely
unknown. Here, we show that focal adhesion kinase (FAK) transduces integrin activation and supports hESC survival, substrate adhesion,
andmaintenance of the undifferentiated state. After inhibiting FAK kinase activity we show that hESCs undergo cell detachment-depen-
dent apoptosis or differentiation. We also report deactivation of FAK downstream targets, AKT and MDM2, and upregulation of p53, all
key players in hESC regulatory networks. Loss of integrin activity or FAK also induces cell aggregation, revealing a role in the cell-cell in-
teractions of hESCs. This study provides insight into the integrin signaling cascade activated in hESCs and reveals in FAK a key player in
the maintenance of hESC survival and undifferentiated state.INTRODUCTION
Human embryonic stem cells (hESCs) are pluripotent stem
cells that exhibit epithelial-like features resembling the
epiblast epithelium of the post-implantation embryo
(Nichols and Smith, 2009). Similarly to epithelial cells,
hESCs are dependent on E-cadherin-mediated cell-cell con-
tacts and anchorage to the extracellular matrix (ECM) via
integrin receptors (Ohgushi et al., 2010; Braam et al.,
2008). Various studies have established the efficacy of in-
tegrin engagement with ECM substrates in supporting
hESC self-renewal and pluripotency (Braam et al., 2008;
Baxter et al., 2009; Miyazaki et al., 2012; Soteriou et al.,
2013; Rodin et al., 2014). However, the specific nature
and role of downstream signaling from integrins in hESCs
remains largely unexplored.
One of the key functions of the ECM in epithelial cells
is to prevent a common form of apoptosis, anoikis, or
‘‘homelessness’’ of cells that have lost contact with the
matrix (Frisch and Francis, 1994). Anoikis is executed
via the mitochondrion and results in activation of cas-
pase downstream of integrin-associated pathways (Gil-
more et al., 2000). ECM-integrin interaction initiates
signaling, promoting the assembly of cytoplasmic scaf-
fold and kinase proteins at focal adhesions near active
integrin clusters (Giancotti and Ruoslahti, 1999). Focal
adhesion kinase (FAK), a protein tyrosine kinase, is one
of the principal integrin signaling regulators, containing
three domains: the protein 4.1, ezrin, radixin, moesinStem C
This is an open access arti(FERM) domain, the kinase domain, and the focal adhe-
sion targeting domain (Frame et al., 2010). Upon integrin
activation FAK localizes at the adhesion site where struc-
tural changes displace the inhibitory FERM, allowing
autophosphorylation of the Tyr397 (Y397) site, leading
to the activation of its intrinsic kinase function and
the formation of docking sites for multiple downstream
signaling molecules (Frame et al., 2010). Several signaling
players directly interact with the Y397 site, e.g., Src,
which in turn phosphorylates FAK, promoting further
activation, or p130Cas, Grb2, and phosphatidylinositol
3-kinase (PI3K), involved in controlling cytoskeletal rear-
rangements, cell cycle, and survival (Parsons, 2003). FAK
is crucial in preventing anoikis through direct activation
of PI3K, via the Y397 site, in turn promoting the pro-sur-
vival AKT cascade (Gilmore et al., 2000; Xia et al., 2004).
FAK can also leave focal adhesions and act in a kinase-in-
dependent manner by localizing in the nucleus where
the FERM scaffolds the AKT target MDM2 for ubiquitina-
tion of pro-apoptotic p53, leading to its protein degrada-
tion (Lim et al., 2008).
Among the repertoire of integrins, the b1-integrin sub-
unit mediates the attachment of hESCs to fibronectin via
the a5b1 heterodimer (Baxter et al., 2009), as well as other
commonly used ECM (Braam et al., 2008). Although hESCs
cultured on ECM have been shown to express active FAK
and AKT (Miyazaki et al., 2012; Rodin et al., 2014;
Wrighton et al., 2014), the functional contribution of the
FAK pathway to hESCs has not been dissected.ell Reports j Vol. 7 j 167–176 j August 9, 2016 j ª 2016 The Authors. 167
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Here, we show that integrin activation in hESCs is trans-
duced by FAK to regulate adhesion and prevent the onset of
anoikis or differentiation via an AKT/MDM2/p53 cascade.
Together, our results reveal a critical role for FAK in the
control of hESC fate, as a mediator of integrin signaling
crosstalk with key hESC regulatory players.RESULTS
Matrix-Integrin Binding Activates FAK Signaling
Upstream of AKT
To characterize integrin signaling in hESCs cultured on
fibronectin, we investigated FAK activation. Immuno-
fluorescence analysis of phosphorylation sites marking
FAK activity showed widespread expression of the au-
tophosphorylation Y397 site, induced upon integrin
engagement in OCT4-positive cells (Figure 1A). Other
phosphorylated residues, created by Src kinase binding
to FAKY397 during adhesome assembly, were expressed
in a small proportion of cells (Figure S1A) showing that
hESCs display active FAK signaling. Importantly, hESCs
express high levels of active b1-integrin and the focal
adhesion marker paxillin but in a diffuse or punctate dis-
tribution, while upon differentiation focal adhesions are
visible (Figure S1B). Next, we asked whether FAKY397 is
a transducer of fibronectin/b1-integrin binding. hESCs
grown on fibronectin had active FAKY397 and its
downstream PI3K target AKT Ser473 (S473) (Figure 1B).
Conversely, plating hESCs on a non-integrin-activating
substrate, Poly-L-Lysine, or blocking b1-integrin selec-
tively with antibody (MAB13), which we previously
showed induces hESC detachment from fibronectin
(Baxter et al., 2009), reduced FAK and AKT activity (Fig-
ures 1C and 1D). We then applied a selective FAK inhibi-
tor, PF562271, which reduced pFAKY397 in a dose-depen-
dent manner (Figures S1C and S1D). Pharmacological
inhibition of 80% of FAKY397 with PF562271 at 2 mM
(FAKi) was comparable with blocking b1-integrin in reduc-
tion of FAK activity (Figures 1C and 1D) without affecting
the potential off-target CDK1 (Figure S1E). Moreover, after
FAK inhibition there was a reduction of pAKT similar to
that seen following integrin inhibition or on Poly-L-
Lysine (Figures 1C and 1D). In summary, our data indicate
that integrin engagement in hESCs is transduced through
FAKY397 and its downstream kinase, AKT (Figure 1E).Inhibition of FAK Signaling Induces Cell Blebbing and
a Caspase-Dependent Anoikis
Autophosphorylation of FAK is crucial for the transduction
of survival signals by recruiting PI3K that in turn induces
the AKT cascade (Xia et al., 2004). Since our data suggested
that FAKY397 transduces integrin activation to AKT, we168 Stem Cell Reports j Vol. 7 j 167–176 j August 9, 2016next determined whether FAK kinase activity supports sur-
vival of hESCs. hESCs responded to FAK kinase block with
PF562271 by detaching from the matrix (Figure 2E) and
undergoing apoptosis in a dose-dependent manner (Fig-
ure 2A). At the same time, we excluded the possibility
that the FAK/Src complex mediated survival, since inhi-
bition of Src did not induce cell detachment and dephos-
phorylation of AKT even if its target FAKY861 was
decreased (Figures S2A and S2B). Similarly, inhibition of
the integrin-associated pseudokinase ILK, reported to
target AKT in differentiating hESCs (Wrighton et al.,
2014), did not affect cell attachment or survival (Fig-
ure S2C). Furthermore, inhibition of ILK did not affect plu-
ripotency markers over time (Figure S2D).
To further confirm that the inhibition of FAK kinase is
responsible for apoptosis of hESCs, we tested in parallel
two other selective FAK inhibitors in both hESCs and hu-
man induced pluripotent stem cells (hiPSCs) with a high-
throughput assay that measures early caspase activation.
All tested FAK inhibitors induced caspase activity in pro-
portion to dose in both hESCs (Figure 2B) and hiPSCs (Fig-
ure S2E). In addition, selective inhibitors of AKT induced
caspase activity in a similarmanner (Figure 2C), supporting
AKT as an effector of FAK. Finally, by measuring together
caspase activity, viability, and cytotoxicity after FAKi, we
found that caspase activity was induced without non-
specific cytotoxicity (Figure S2F).
To validate whether FAK-dependent apoptosis relies
on caspase activity, we applied the caspase inhibitor
Z-VAD-FMK to hESCs treated with FAKi. Immunostaining
confirmed that FAKi induced cleaved caspase-3 expression
that was inhibited by Z-VAD-FMK (Figure 2D). Floating
dead cells, normally present after FAKi, were abolished
by Z-VAD-FMK but instead, attached single and groups
of hESCs, with prominently blebbing membranes, were
observed (Figure 2E). The effects of FAKi on survival, cell
blebbing, and caspase activation were confirmed on vitro-
nectin (Figures S2G and S2H).
Cell blebbing is an indicator of cytoskeletal contraction,
commonly a result of caspase-3 cleavage of ROCK during
apoptosis, leading to increased contractility (Coleman
et al., 2001). Our data indicate that FAK inhibition induced
cell blebbing independently of caspase, a unique mecha-
nism reported in hESCs after cell-cell dissociation (Ohgushi
et al., 2010), but also observed by us in groups of cells. How-
ever, caspase activity is required to complete detachment
from the ECM, a key feature of anoikis. Moreover, Z-VAD-
FMK also rescued FAKi-dependent early (Annexin V) and
late (Annexin V/7-AAD) apoptosis, increasing the propor-
tion of live cells, suggesting a suppression of hESC cas-
pase-dependent turnover (Figure 2F). Overall, these results
show that FAK kinase activity is required to suppress a cas-
pase-dependent anoikis in hESCs.
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Figure 1. Matrix-Integrin Binding Acti-
vates FAK Signaling Upstream of AKT
(A) Immunofluorescence of hESCs cultured
on fibronectin for 24 hr and stained with
antibodies against OCT4 and pFAKY397.
Scale bar, 50 mm.
(B) Immunoblot of pFAKY397, FAK,
pAKTS473, and AKT in hESCs stably cultured
on fibronectin.
(C) Immunoblot of pFAKY397, FAK,
pAKTS473, and AKT in hESCs 1 hr after being
plated in the following conditions, on:
fibronectin (CTL); fibronectin plus 10 mg/mL
of b1-integrin blocking antibody (MAB13);
non-integrin activating Poly-L-Lysine sub-
strate or fibronectin plus 2 mM PF562271
(FAKi).
(D) Densitometry of immunoblots for
pFAKY397/FAK ratio and pAKTS473/AKT
ratio for the conditions in (C). Data repre-
sent mean + SEM (n = 3 experiments). *p <
0.05 relative to CTL.
(E) Integrin signaling cascade and points of
inhibition.
See also Figure S1.Loss of Total FAKDisrupts hESCAttachment and Leads
to Cell Aggregation
Since FAK is a modular protein that functions as a scaffold
during adhesome assembly linking integrins to the actin
cytoskeleton, we investigated the effect of substantially
reducing total FAK on hESCs. Knocking down FAK protein
by 70% using small interfering RNA (siFAK) (Figure 2G)induced visible changes in morphology and decreased
hESC attachment to fibronectin. Cells formed aggregates
similar to those seen after blocking b1-integrin with anti-
body (Figure 2H), showing that integrin/FAK is required
for the transmission of attachment cues in hESCs. More-
over, cell aggregates were also produced in hESCs grown
on vitronectin, after blocking its receptor aVb5-integrinStem Cell Reports j Vol. 7 j 167–176 j August 9, 2016 169
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with antibody (Figure S2I). Similarly to the effect of
MAB13, pFAK activity was downregulated after inhibition
of vitronectin-integrin binding (Figure S2J), suggesting
that a common downstream FAK signaling may be acti-
vated. Furthermore, apoptosis was increased by both
MAB13 and siFAK (Figures 2K and 2I), although late
apoptotic cells are fewer in the latter (Figure 2J), strongly
supporting the role of b1-integrin and FAK in survival of
hESCs. In conclusion, loss of b1-integrin activity or FAK
produces a shift frommatrix-cell adhesion to cell-cell adhe-
sion with lowered survival, highlighting the role of integ-
rin/FAK signaling in the maintenance of pro-survival
adhesion cues in hESCs.
FAK Localizes in the Nucleus of hESCs and Regulates
MDM2/p53 Levels during Anoikis
The results reported in Figures 1C and 2A link FAK inhibi-
tion with the downregulation of AKT and a subsequent
apoptotic response. It has been reported that de-adhesion
or kinase inhibition promotes nuclear accumulation of
FAK (Lim et al., 2012), which exercises kinase-independent
functions, including scaffolding MDM2 ubiquitination of
p53 as an additional mechanism to support survival (Lim
et al., 2008). To test whether FAKparticipates in this process
in hESCs, we first determined its cellular location. Immu-
nofluorescence of hESCs with total FAK antibody revealed
a diffuse distribution in the cytoplasm but also in the
nucleus, while FAKY397 localized at the cell surface (Fig-
ure 3A). Accordingly, FAK was repeatedly found in the nu-
clear fraction of hESCs (Figure 3B). After 6 hr of integrin
blocking or FAK inhibition, total FAK did not accumulate
in the nucleus, but was reduced in the cytoplasm and
also slightly so in the nucleus (Figures 3C and S3A). Immu-
nofluorescence also showed a widespread loss of FAK after
1 hr from integrin/FAK inhibition (Figure 3D). Moreover,
inhibition of integrin/FAK deactivated pMDM2while upre-Figure 2. Inhibition of FAK Signaling Induces Cell Blebbing and a
(A) Quantification of Annexin V/7-AAD positive cells by flow cytome
PF562271, DMSO, or untreated. *p < 0.05 relative to DMSO.
(B) Caspase activity in hESCs treated for 5 hr with the indicated conc
(C) Caspase activity in hESCs treated for 5 hr with the indicated conc
(D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi o
(E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or w
cells (b). Scale bar, 100 mm.
(F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for
(G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock
siFAK for 48 hr. Bottom: protein knockdown efficiency. *p < 0.05.
(H) Top: phase images of hESCs after knockdown with b2-microglob
treatment with 10 mg/mL of IgG isotype or MAB13 antibody for 24 h
(I) Quantification of Annexin V-positive hESCs after knockdown with
(J) Quantification of Annexin V/7-AAD-positive hESCs after knockdow
(K) Quantification of Annexin V/7-AAD-positive hESCs treated with I
Data represent mean + SEM (n = 3 experiments). See also Figure S2.gulating p53 (Figure 3E). The elevation of p53 protein was
detectable already after 1 hr of treatments (Figure S3B), and
we observed its increase mainly in the nucleus (Figure 3F).
Furthermore, p53 upregulation appears linked to the
reduced MDM2 ubiquitin ligase activity, since FAK inhibi-
tion reduces the poly-ubiquitin chains associated with
p53 (Figure 3G). In conclusion, attachment of hESCs to
the ECM supports FAK kinase and total protein expression,
which keeps MDM2 active and p53 low, ultimately pre-
venting a caspase-dependent anoikis.
hESCs Avoid Anoikis by Exiting Their
Undifferentiated State
We have demonstrated that integrin signaling regulates
survival of hESCs, but does it play a role in maintaining
the undifferentiated stem cell state? First, we found that af-
ter 24 hr of FAKi the entire population of apoptotic hESCs
retained the pluripotency-associated marker NANOG (Fig-
ure 4A). However, when hESCs were cultured in the pres-
ence of FAKi for 3 days, a subpopulation of cells that
remained attached and escaped anoikis had acquired a
differentiated morphology (Figures 4B and S4A). Indeed,
the cells were NANOG negative and had elongated nuclei
after 2 or 1 mMof FAKi (Figures 4C and S4C). Similar results
were obtained on vitronectin and laminin (Figure S4D).
Strikingly, FAKi-differentiated cells dramatically downregu-
lated FAK andNANOGproteinswhile pSMAD2was slightly
increased (Figure 4D). At the gene-expression level, FAKi
reduced both NANOG and OCT4 pluripotency-associated
genes (Figures 4E and S4B). In parallel, early differentiation
genes were upregulated (Figure 4E). Consistent with the
role of FAK downstream of integrins, blocking b1-integrin
also induced differentiation in a similar fashion (Fig-
ure 4F). Integrin-blocked aggregates were comparable
with embryoid bodies (EBs) in the induction of differen-
tiation, although EBs showed a greater induction ofCaspase-Dependent Anoikis
try in hESCs treated for 24 hr with the indicated concentrations of
entration of FAK inhibitors. *p < 0.05 relative to DMSO.
entration of AKT inhibitors. *p < 0.05 relative to DMSO.
nly, or with 50 mM ZVAD-FMK for 24 hr. *p < 0.05 relative to DMSO.
ith Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of
24 hr with DMSO, FAKi only, or with Z-VAD-FMK.
control, control GFP vector (ctl vector) plus FAK siRNA (siFAK), or
ulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after
r. Scale bars, 100 mm (top) and 50 mm (bottom).
siB2M or siFAK (66 hr). **p < 0.03.
n with siB2M or siFAK (66 hr).
gG or MAB13 antibody (24 hr). *p < 0.05.
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differentiation markers at day 3 (Figure 4F), but similar to
MAB13 inhibited aggregates at day 5 (Figure S4E). Together,
these data show that hESCs undertake one of two routes
after inhibition of integrin/FAK signaling: they die through
anoikis, remaining undifferentiated, or survive but differ-
entiate, losing characteristic hESCs morphology and
markers. Our data highlight a model of hESC regulation
by integrin signaling (Figure 4G) with FAK as amajor trans-
ducer of integrin cues for attachment, survival, and main-
tenance of stem cell identity.DISCUSSION
Here we shed light on the events downstream of integrin
activation in hESCs and reveal in FAK the mediator of
this signaling and a positive regulator of survival, adhesion,
and stem cell maintenance. Indeed, hESCs respond to FAK
inhibition by exiting the stem cell state through either
anoikis or differentiation. We found that integrin activa-
tion in hESCs is transduced by FAKY397 to activate AKT
and MDM2 and suppress p53 and caspase activation. This
FAK-dependent survival pathway is consistent with that re-
ported in adult cell types (Lim et al., 2008), but in the
context of hESCswe reveal how integrin signaling supports
pluripotency circuits, since AKTand p53 are well known to
regulate the balance between self-renewal and differentia-
tion (Singh et al., 2012; Jain et al., 2012). We found no ev-
idence that the loss of FAK signaling in pluripotent cells
biases differentiation to a particular lineage, but rather
the resultant switch-off of PI3K/AKT and switch-on of
p53 can shift hESCs out of pluripotency (Singh et al.,
2012; Jain et al., 2012).
Our data confirm and extend previous work reporting
FAK and AKT phosphorylation in hESCs (Miyazaki et al.,
2012; Rodin et al., 2014; Wrighton et al., 2014). However,
a recent paper reported that FAK is activated only upon dif-
ferentiation (Villa-Diaz et al., 2016), similarly to murineFigure 3. FAK Localizes in the Nucleus of hESCs and Regulates M
(A) Wide-field fluorescence microscopy images of hESCs co-stained
bar, 20 mm.
(B) Immunoblot of FAK in the nuclear and cytoplasmic fraction of hESC
(N) enriched marker.
(C) Immunoblot of FAK in the nuclear and cytoplasmic fraction of hE
represent mean + SEM (n = 3 experiments). *p < 0.05.
(D) Immunofluorescence images of hESCs treated with DMSO, FAKi, IgG
against FAK. Arrows indicate areas with less FAK staining. Scale bar,
(E) Immunoblot of pMDM2, p53, and b-tubulin in hESCs treated with
(F) Fluorescence microscopy images of hESCs treated with DMSO, FA
antibody against p53. Scale bars, 50 mm.
(G) Immunoblot of ubiquitinated p53 immunoprecipitated from hESC
See also Figure S3.ESCs where stem cell maintenance inversely correlates
with integrin activation (Toya et al., 2015). This discrep-
ancy with our and previous reports on hESCs may be
explained by our data showing that the integrin signaling
players are indeed active in hESCs but are only assem-
bled into obvious focal adhesions upon differentiation.
Clearly, hESCs manipulate complex integrin machinery
for different purposes in different environments. For
example, it was shown that ILK inhibition but not FAK in-
hibition increased endoderm differentiation in the pres-
ence of activin A (Wrighton et al., 2014), whereas we saw
no effect of ILK on survival or differentiation when added
to hESC media.
We found that hESCs require FAK for maintenance of
substrate adhesion, which is consistent with its role in
transmitting forces from integrins to the cytoskeleton (Hu-
veneers andDanen, 2009). Double inhibition of FAK kinase
and caspase revealed signs of cytoskeletal hypercontrac-
tion, similar to the unique and lethal hESC-response to sin-
gle-cell dissociation (Ohgushi et al., 2010), but also visible
in groups of mutually adhering cells. Thus, our results
suggest that integrin signaling is an essential yet distinct
cue from cell-cell adhesion for suppression of cytoskeleton
contraction and apoptosis. However, integrin signaling
may crosstalk with cell-cell adhesion. Indeed, we observed
formation of cell aggregates after blocking b1-integrin or
FAK knockdown.
Finally, we discovered that hESCs possess a nuclear
pool of FAK that does not accumulate but reduces after
FAK inhibition, unlike in adult cells (Lim et al., 2012). We
propose that hESCs utilize non-canonical FAKmechanisms
to quickly respond to defective adhesion, which could
involve undiscovered roles for nuclear FAK in the context
of pluripotent cells.
In conclusion, this study shows that the ECM exerts
extensive control over feeder-free hESCs via a FAK-depen-
dent cascade linking integrins to intrinsic regulatory
players, supporting survival and maintenance of stem cellDM2/p53 Levels during Anoikis
with DAPI and antibodies against pFAKY397 and total FAK. Scale
s. b-tubulin serves as cytoplasmic (C) marker and NANOG as nuclear
SCs treated with DMSO or FAKi for 6 hr. Graph: densitometry. Data
, or MAB13 for 1 hr. Cells were co-stained with DAPI and antibodies
50 mm.
DMSO, FAKi, IgG, or MAB13 for 6 hr.
Ki, IgG, or MAB13 for 1 hr. Cells were co-stained with DAPI and
s treated with or without FAKi for 6 hr.
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identity. This study advances our understanding of the un-
derlying integrin signaling controlling hESCs, of particular
importance for their culture on ECM for both basic and
translational research.EXPERIMENTAL PROCEDURES
Cell Culture
hESCs HUES1 (Harvard University), MAN5 (North West Embry-
onic StemCell Center), Shef-1 (University of Sheffield), and hiPSCs
Sendai J (Neusentis) were cultured in defined mTSER1 (Life Tech-
nologies)mediumon 50 mg/mL fibronectin as previously described
(Baxter et al., 2009). Cells were passaged with TryPLE express
(Gibco) at a ratio of 1:3. HUES1 was used as lead line throughout
the study, MAN5 was used when specified, and Shef1 and SendaiJ
to confirm compound screening. For selected experiments, hESCs
were plated on 5 mg/mL of vitronectin-N (Life Technologies) or
laminin 521 (Biolamina).
Integrin Blocking
hESCsweredissociatedand seededatadensityof0.73104 cells/cm2
in hESCmedia supplemented with 10 mg/mLMAB13 anti b1-integ-
rin antibody (M. Humphries, University of Manchester) or rat
immunoglobulinG (IgG) isotype (Sigma) andplatedonfibronectin.
For cells cultured on vitronectin, aVb5-integrin was inhibited with
10 mg/ml MAB1916z blocking antibody (Millipore) or mouse IgG
isotype (Sigma). For antibody-free and EB controls, hESCs were
seeded at the same density on either fibronectin-coated or non-
adherent tissue-culture plates, respectively.
Compound Screening
Cells were prepared 24 hr before the assay by passaging in pres-
ence of Y-27632 (10 mM) (Sigma-Aldrich) to a fibronectin-coated
96-well plate (Cell-BIND, Corning) at a density of 2 3 104 cells/
well. Cells were treated in triplicate with FAK or AKT inhibitors,
at the concentrations indicated in the figures, added to mTESR1
medium, and incubated for 5 hr at 37C. The ApoToxGlo Triplex
assay (Promega) was used according to the manufacturer’s instruc-
tions. Signals were analyzed with a SpectraMax M5 reader (Molec-
ular Devices).Figure 4. hESCs Avoid Anoikis by Exiting Their Undifferentiated
(A) Quantification of Annexin V/NANOG double-positive hESCs treate
(B) Phase images of hESCs treated with DMSO or FAKi for 3 days. Sca
(C) Immunofluorescence images of hESCs treated with DMSO or FAKi
NANOG. Scale bar, 50 mm.
(D) Immunoblot of FAK, pSMAD2, and NANOG in hESCs treated with D
(E) Gene expression showing fold change for pluripotency-associated
SOX17, Goosecoid, and FOXA2 in hESCs treated with DMSO or FAKi for
(F) Gene expression fold change for pluripotency-associated and early
MAB13 or IgG control for 3 days. *p < 0.05, MAB13 relative to IgG an
(G) Proposed model for FAK signaling in hESCs: ECM-integrin binding
cascade leading to suppression of p53. In absence of FAK activity, t
caspase-dependent anoikis or downregulation of hESCs core genes an
Data represent mean + SEM (n = 3 experiments). See also Figure S4.siRNA Knockdown
hESCs were treated with 10 mM Y27632 (Sigma-Aldrich) for
1 hr and nucleofected with Amaxa Nucleofector following the
manufacturer’s instructions (Lonza), with target-specific FAK
siRNA (sc-29310, Santa Cruz Biotechnology) at a final concentra-
tion of 200 nM, b-2-microglobulin siRNA control (Life Technolo-
gies), or pmaxGFP control vector (Lonza). Medium was changed
the following day and experimental analysis performed 66 hr later.
Statistics
Data were analyzed with Student’s t-test using GraphPad Prism. p
values of <0.05 were considered significant.
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d for 24 hr with DMSO or FAKi. *p < 0.05.
le bar, 100 mm.
for 3 days. Cells were co-stained with DAPI and antibody against
MSO or FAKi for 3 days.
markers NANOG and OCT4 and early differentiation markers PAX6,
3 days. *p < 0.05 relative to DMSO.
differentiation markers [as in (E)] in hESCs treated with 10 mg/ml of
d EBs relative to hESCs; n.s., not significant.
activates FAK, which induces PI3K upstream of AKT/MDM2 survival
he concomitant switch-off of AKT and elevation of p53 induces a
d differentiation.
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Figure S1. Matrix-Integrin Binding Activates FAK Signaling Upstream of AKT 
(Related to Figure 1) 
 
(A) Immunofluorescence images of hESCs cultured on fibronectin and stained with antibodies against OCT4 and 
pFAKY407, pFAKY576, pFAKY577 or pFAKY861. Scale bars 50 µm 
(B) Immunofluorescence image of undifferentiated and differentiated hESCs cultured on fibronectin and stained with 
antibodies against Paxillin, Actin and active β1-integrin. For differentiation, cells were grown in hESCs media (Baxter et al., 
2009) without NT4 and AA for 7 days. Scale bar 50 µm 
(C) Immunoblot of pFAKY397 and FAK after increasing concentrations of PF562271 inhibitor added for 1 h. 
(D) Dose-response curve of pFAKY397 relative to PF562271 concentration added for 1 h. Average of 3 independent 
experiments. *indicates p<0.05.  
(E) Immunoblot of CDK1 and β-tubulin after 3 hr of 2 µM PF562271.  
 
Data represented as mean +SEM 
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FIGURE S2 
Dose-response to FAK inhibitors in Sendai J cells on Fibronectin (5h)
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Figure S2. Inhibition of FAK Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (Related to Figure 2) 
 
(A) Top: Immunoblot of pSrc416 and GAPDH in hESCs treated with DMSO or Src inhibitor pp60 at 10nM or 25nM for 1h, 
2h or 24hr. Bottom: Immunoblot of pSrc416, pFAKY861, pAKT and β-tubulin in hESCs treated with DMSO or pp60 
(25nM) for 1 and 2 hr. 
(B) Phase images of hESCs plated on fibronectin for 24 hr in presence of Src inhibitor pp60 (25 nM) or DMSO control. 
Scale bars 100 µm 
(C) Quantification of cell detachment (cell in suspension) and survival (dead cells stained positive with trypan blue) in hESCs 
treated for 24 hr with 0.4 µM of ILK inhibitor cpd22. (n=3 independent experiments). 
(D) Immunofluorescence images of hESCs treated with DMSO or 0.4 µM cpd22 for 3 days and stained with antibody against 
OCT4. 
(E) Caspase activity in hiPSCs treated for 5 hr with the indicated concentrations of FAK inhibitors. *indicates p<0,05 (n=3 
independent experiments). 
(F) Scatter plots of viability, cytotoxicity and caspase activity measured in parallel in hiPSCs treated with DMSO or 2 µM 
of PF562271 for 5 hr. Each dot represents a well of a 96-well plate.  
(G) Phase images of hESCs cultured on vitronectin substrate and treated for 24 hr with DMSO, FAKi only or with Z-VAD-
FMK. Inserts from left to right show: hESCs colony, cells undergoing anoikis and cell blebbing. Scale bar 50 µm 
(H) Cleaved-caspase 3 expression in hESCs cultured on vitronectin and treated with DMSO, FAKi only or with Z-VAD-
FMK for 24 hr. *indicates p<0.05 relative to DMSO (n=3 independent experiments). 
(I) Phase images of hESCs replated on vitronectin for 45 mins or 24 hr in presence of 10 µg/ml of MAB1916z or mouse IgG 
control versus untreated control. Scale bars 100 µm. 
(J) Immunoblot of pFAKY576 or β-tubulin in hESCs cultured on vitronectin from 1 to 3 days (3d) with 10 µg/ml of IgG 
control or MAB1916z. 
 
Data represented as mean +SEM 
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FIGURE S3 
 
 
 
Figure S3. FAK Localizes in the Nucleus of hESCs and Regulates MDM2/p53 Levels during Anoikis (Related to 
Figure 3) 
 
(A) Immunoblot of FAK in the nuclear and cytoplasmic fraction of hESCs treated with IgG control or MAB13 for 6 hr. β-
tubulin serves as cytoplasmic marker (C) and PARP as nuclear marker (N).  
(B) Immunoblot of p53 and GAPDH in control hESCs versus cells treated with FAKi or MAB13 for 1 hr. 
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FIGURE S4 
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Figure S4. hESCs Avoid Anoikis by Exiting their Undifferentiated State (Related to Figure 4) 
 
(A) Phase images of hESCs MAN5 treated with DMSO or 2 µM of PF562271 (FAKi) for 3 days. Scale bar 100 µm. 
(B) Gene expression fold-change of pluripotency markers NANOG and OCT4 in hESC MAN5 treated with DMSO or 
FAKi for 3 days. * indicates p<0,05 (n=3 independent experiments). 
(C) Immunofluorescence images of hESCs cultured on fibronectin and treated with DMSO or 1 µM PF562271 for 3 days. 
Cells were costained with DAPI and antibodies against NANOG and OCT4. Scale bars 200 µm. 
(D) Immunofluorescence images of hESCs cultured on vitronectin or laminin 521 and treated with DMSO or 2 µM PF562271 
for 3 days. Cells were costained with DAPI and antibodies against NANOG and OCT4. Scale bars 200 µm. 
(E) Gene expression fold-change of pluripotency markers NANOG, OCT4 and differentiation markers 
PAX6, SOX17, FOXA2 and SOX1 in hESC HUES1 treated with DMSO, FAKi, 10µg of MAB13 or rat 
IgG for 5 days. * indicates p<0,05. MAB13 relative to IgG, EB relative to hESCs (n=3 independent experiments) 
 
Data represented as mean +SEM 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Apoptosis assay and Flow Cytometry: 
Apoptosis measurements were performed using the Annexin V-PE and 7-AAD kit (BD Pharmigen) and acquired on a Lab 
Quanta SC flow cytometer (Beckman Coulter). For Annexin V/NANOG double staining, samples were pre-stained with 
Annexin V for 15 mins and washed 3 times with PBS 1X prior to fixation. For intracellular staining, cells were fixed in 4% 
paraformaldehyde at room temperature and permeabilized in 70% MeOH at 4°C. Samples were probed with Nanog-PE or 
AlexaFluor 488 Isotype control (both from BD Pharmigen) for 30 mins and analysed. Data were analysed using Summit 4.3 
(Beckman Coulter). 
 
Immunofluorescence: 
hESCs were fixed in 4% paraformaldehyde, blocked with 10% serum matching the species of the secondary antibody and 
permeabilised with 0.1% TritonX-100. Cells were incubated with primary antibodies dilutions containing 1% serum 
overnight at 4°C. Cells were washed and incubated with secondary antibodies conjugated with Alexa fluorophores 
(Invitrogen) and nuclei stained with DAPI (Sigma). Images were taken with Olympus 1X71 inverted microscope (Olympus) 
with a Q-imaging Retiga SRV camera and processed using QCapture Pro (QImaging) and ImageJ 64. 
 
Widefield restoration microscopy with Delta Vision: 
hESCs were grown and fixed on glass-bottom culture dishes (35.0/10mm Grainer Bio-one) coated with fibronectin. Images 
were acquired on a Delta Vision Olympus 1X71 microscope (Applied Precision) restoration microscope using a 100x/140 
Uplan S Apo objective and the Sedat Quad filter set. The images were collected using a Coolsnap HP (Photometrics) camera 
with a Z optical spacing of 0.2 µm. 
 
Antibodies and reagents: 
Immunofluorescence antibodies were used against: Paxillin (BD Bioscience), F-Actin (Fluorescein phalloidin, Invitrogen), 
activated β1-integrin 12g10 (gift from prof. M.Humphries, Wellcome Matrix Centre, The University of Manchester), 
NANOG (R&D Systems); OCT4 (BD Biosciences); FAK clone 4.47 (Millipore); pFAKY397, pFAKY407, pFAKY576, 
pFAKY577 and pFAKY861 (Invitrogen); p53 (ab131442, Abcam), Cleaved-caspase3 (Asp175, Cell Signalling). 
Western blotting antibodies were against: FAK, pFAKY397, pFAK576, pSrc416, pAKTSer473, p53, pMDM2, NANOG (all 
from Cell Signalling); pFAK861 (Invitrogen); CDK1 (R&D); GAPDH 71.1 (Sigma Aldrich); AKT (Invitrogen); pSMAD2 
(Millipore); Multiubiquitin Chain MoAb (clone FK2, Cayman chemical); β-tubulin (Li-COR). Secondary antibodies: IRDye 
680LT Goat anti-Mouse IgG; IRDye 800CW Goat anti-Rabbit IgG (Li-COR), IRDye 680LT Donkey anti-Goat IgG. 
Small molecules: FAK inhibitors PF-562271 (Roberts et al., 2008), PF-06405780 (Bunnage et al., 2011), PF-04557611 
(Lovering et al., 2012); AKT inhibitors PF-05094152 (Heerding et al., 2008), PF-04907559 (Heerding et al., 2007) and PF-
04943582 (Zhu et al., 2007) were all provided by Pfizer. ILK inhibitor cpd22 from Calbiochem. Src inhibitor pp60 (521-533) 
from Tocris. Caspase inhibitor Z-VAD-FMK from Abcam. 
 
Protein extraction and immunoblotting: 
Adherent cells were lysed on ice in RIPA buffer (Sigma) with added protease and phosphatase inhibitors (ROCHE). Protein 
extracts were quantified using the BCA protein detection kit (Thermo Scientific). Equal protein amounts were separated on 
12% poly-acrylamide gel and transferred to a nitrocellulose membrane (Wathman). Membranes were blocked in Odyssey 
buffer (Li-COR), incubated overnight at 4°C with primary antibody, washed and incubated with IRDye conjugated secondary 
antibodies for 2 hr at room temperature. Membranes were scanned with the Odyssey detection system (Li-COR). 
 
Subcellular fractionation: 
hESCs pellets were lysed in NER-PER extraction reagents (Thermo Scientific). Cell pellet were resuspended in 200 µl of 
CERI buffer plus protease and phosphatase inhibitors (ROCHE) for 10 mins on ice. CERII buffer was added to the solution, 
vortexed for 15 mins, incubated 2 mins on ice, vortexed 5 sec and spun at 500 g for 7 mins. Cytoplasmic proteins were 
collected from the supernatant. The remaining nuclear pellet was washed twice in PBS, spun at 500 g for 7 min and 
incubated in 50 µl of NER buffer for 40 mins on ice, vortexed every 10 mins. Nuclear proteins were collected in the 
supernatant after a 16,000 g centrifugation for 10 mins at 4°C. 
 
Immunoprecipitation: 
hESCs pellet corresponding to 5 x 106 cells was used for each immunoprecipitation condition following the p53 
immunocapture kit (ab154470, Abcam). For each immunoprecipitation, 10 µl of p53 beads slurry were used in a 1.5 ml tube 
incubated under rotation for 16 hr at 4°C. 
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Real-time PCR: 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and converted to cDNA with the M-MLV reverse transcriptase 
(Promega). For qPCR mastermixes, power SYBR Green Master Mix (Applied Biosystems) was used and plates were run 
using the CFX96 Real‐Time System (Bio‐Rad). mRNA levels were normalized to GAPDH expression and relative 
expression calculated as fold‐change from the untreated control. 
 
 
Table S1. Primer set used in this study, Related to Figure 4 
GENE FORWARD REVERSE 
OCT4 AGACCATCTGCCGCTTTGAG GCAAGGGCCGCAGCTT 
NANOG GGCTCTGTTTTGCTATATCCCCTAA CATTACGATGCAGCAAATACAAGA 
GAPDH ATGGGGAAGGTGAAGGTCG TAAAAGCAGCCCTGGTGACC 
PAX6 CTGGCTAGCGAAAAGCAACAG CCCGTTCAACATCCTTAGTTTATCA 
SOX17 AGAGATTTGTTTCCCATAGTTGGATT TGTTTTGGGACACATTCAAAGCT 
SOX1 GCGGTAACAACTACAAAAAACTTGTAA GCGGAGCTCGTCGCATT 
FOXA2 TTCAGGCCCGGCTAACTCT AGTCTCGACCCCCACTTGCT 
Goosecoid GATGCTGCCCTACATGAACGT GACAGTGCAGCTGGTTGAGAAG 
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